In recent years, glucagon-like peptide- 1 (GLP 1) analogue injectable treatment for type 2 diabetes has been introduced to overcome some potential barriers associated with insulin medication initiation and adherence, such as weight gain and injection frequency and hypoglycemia. Here, GCG is linked to Hypoglycemia.